Cardiorenal Safety Markers With Injectable Glucagon-Like Peptide-1 (GLP-1) Agonists in Type 2 Diabetes: A Network Meta-Analysis.

Cureus · 2025 · PMC12683079 · PMID 41367446

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Exenatide showed a trend toward renal benefit (OR: 0.87 (0.75-1.01)), while lixisenatide (OR: 1.05 (0.89-1.22)) appeared neutral, with no significant benefit.

also in 53,322 other papers

a nonsignificant trendno p-value reported

In contrast, exenatide showed a nonsignificant trend toward reduction (OR: 0.90; 95% CI: 0.78-1.03), and lixisenatide likewise did not reach significance (OR: 0.77; 95% CI: 0.58-1.03).

also in 5,406 other papers

did not reach statistical significanceno p-value reported

Lixisenatide also ranked highly (SUCRA: 69.1) though its estimate (OR: 0.77 [0.58-1.03]) did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.